IL17A and Pruritus: In a recent systematic review, meta-analysis of 13 studies showed that systemic treatments, including anti-IL-17, JAK inhibitors, adalimumab and apremilast, demonstrate a similar reduction in pruritus, ranging from −4.52 to −2.18 points, in a 0–10-point pruritus scale [35].